Raymond James Forecasts Strong Price Appreciation for HLS Therapeutics (TSE:HLS) Stock

HLS Therapeutics (TSE:HLS) had its price target boosted by Raymond James from C$4.00 to C$5.00 in a report released on Friday,BayStreet.CA reports.

Separately, Stifel Nicolaus reduced their price target on shares of HLS Therapeutics from C$3.75 to C$3.25 in a research report on Tuesday, August 13th.

HLS Therapeutics Stock Performance

TSE:HLS opened at C$3.42 on Friday. The company has a debt-to-equity ratio of 100.44, a current ratio of 2.02 and a quick ratio of 1.01. The firm has a 50-day moving average of C$3.54 and a two-hundred day moving average of C$3.48. The stock has a market cap of C$108.72 million, a P/E ratio of -3.39 and a beta of 1.07. HLS Therapeutics has a 1-year low of C$3.00 and a 1-year high of C$5.48.

About HLS Therapeutics

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.